Trial Profile

A Sequential, Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Male and Female Participants 18 to 55 Years of Age

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 May 2025 Planned End Date changed from 28 Feb 2025 to 28 Sep 2025.
22 May 2025 Planned primary completion date changed from 28 Feb 2025 to 28 Jul 2025.
03 Mar 2025 According to Latigo Biotherapeutics media release, company announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to LTG-001 following positive Phase 1 results which demonstrated a favorable safety, tolerability, and pharmacokinetic profile for LTG-001

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com